Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.

The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.

AstraZeneca and Lilly put PARP1 and KRAS G12C inhibitors into their first phase 3s, while Amgen advances DLL3 into early-stage disease.

Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.

A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.

The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.

Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.

Meanwhile, Bristol Myers Squibb hands back two mystery projects.